ZA200700578B - Method for treating nervous system disorders and conditions - Google Patents
Method for treating nervous system disorders and conditionsInfo
- Publication number
- ZA200700578B ZA200700578B ZA200700578A ZA200700578A ZA200700578B ZA 200700578 B ZA200700578 B ZA 200700578B ZA 200700578 A ZA200700578 A ZA 200700578A ZA 200700578 A ZA200700578 A ZA 200700578A ZA 200700578 B ZA200700578 B ZA 200700578B
- Authority
- ZA
- South Africa
- Prior art keywords
- conditions
- nervous system
- system disorders
- treating nervous
- treating
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59020304P | 2004-07-22 | 2004-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200700578B true ZA200700578B (en) | 2010-06-30 |
Family
ID=35149631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200700578A ZA200700578B (en) | 2004-07-22 | 2007-01-19 | Method for treating nervous system disorders and conditions |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20060020015A1 (https=) |
| EP (1) | EP1773320A1 (https=) |
| JP (1) | JP2008507550A (https=) |
| KR (1) | KR20070034126A (https=) |
| CN (1) | CN101410106A (https=) |
| AU (1) | AU2005266994A1 (https=) |
| BR (1) | BRPI0512186A (https=) |
| CA (1) | CA2574310A1 (https=) |
| IL (1) | IL180731A0 (https=) |
| MX (1) | MX2007000853A (https=) |
| NO (1) | NO20070912L (https=) |
| RU (1) | RU2007102292A (https=) |
| WO (1) | WO2006012474A1 (https=) |
| ZA (1) | ZA200700578B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080081834A1 (en) | 2002-07-31 | 2008-04-03 | Lippa Arnold S | Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders |
| CA2574315A1 (en) * | 2004-07-22 | 2006-02-02 | Wyeth | Method for treating nervous system disorders and conditions |
| AU2005266997A1 (en) * | 2004-07-22 | 2006-02-02 | Wyeth | Method for treating nervous system disorders and conditions |
| US8000005B2 (en) * | 2006-03-31 | 2011-08-16 | Prysm, Inc. | Multilayered fluorescent screens for scanning beam display systems |
| JP2009502798A (ja) * | 2005-07-21 | 2009-01-29 | ワイス | 神経系障害および状態の処置方法 |
| US20080033050A1 (en) | 2006-08-04 | 2008-02-07 | Richards Patricia Allison Tewe | Method of treating thermoregulatory disfunction with paroxetine |
| US9566264B2 (en) | 2013-07-01 | 2017-02-14 | Euthymics Bioscience, Inc. | Combinations and methods |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3166571A (en) * | 1962-06-06 | 1965-01-19 | American Cyanamid Co | 1-phenyl-1, 2-cyclopropane dicarboximides |
| US3344026A (en) * | 1966-05-16 | 1967-09-26 | American Cyanamid Co | Dosage unit composition of 1-(p-chlorophenyl)-1, 2-cyclopropanedicarboximide for relief of depression |
| US3892772A (en) * | 1973-12-04 | 1975-07-01 | American Cyanamid Co | Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use |
| US4088652A (en) * | 1975-07-31 | 1978-05-09 | American Cyanamid Company | Acylazabicyclohexanes |
| US4131611A (en) * | 1975-07-31 | 1978-12-26 | American Cyanamid Company | Azabicyclohexanes |
| US4118393A (en) * | 1977-06-23 | 1978-10-03 | American Cyanamid Company | Phenyl azabicyclohexanones |
| US4118417A (en) * | 1977-06-23 | 1978-10-03 | American Cyanamid Company | Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids |
| GR72713B (https=) * | 1976-09-15 | 1983-12-01 | American Cyanamid Co | |
| US4435419A (en) * | 1981-07-01 | 1984-03-06 | American Cyanamid Company | Method of treating depression using azabicyclohexanes |
| ATE37871T1 (de) * | 1982-12-21 | 1988-10-15 | Ciba Geigy Ag | Substituierte azabicycloalkane, ihre verwendung, pharmazeutische praeparate, welche diese verbindungen enthalten, und verfahren zur herstellung dieser verbindungen. |
| US6204284B1 (en) * | 1991-12-20 | 2001-03-20 | American Cyanamid Company | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies |
| US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| US6150376A (en) * | 1998-08-05 | 2000-11-21 | Georgetown University | Bi- and tri-cyclic aza compounds and their uses |
| DE19919336A1 (de) * | 1999-04-27 | 2000-11-16 | Consortium Elektrochem Ind | Verfahren zur Ringspaltung von Thiazolidinderivaten |
| US6372919B1 (en) * | 2001-01-11 | 2002-04-16 | Dov Pharmaceutical, Inc. | (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent |
| AU2002250058B2 (en) * | 2001-02-12 | 2007-08-16 | Wyeth Llc | Novel succinate salt of O-desmethyl-venlafaxine |
| EP1266659A1 (en) * | 2001-06-11 | 2002-12-18 | Pantarhei Bioscience B.V. | Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes |
| US6569887B2 (en) * | 2001-08-24 | 2003-05-27 | Dov Pharmaceuticals Inc. | (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake |
| UA77234C2 (en) * | 2001-12-05 | 2006-11-15 | Wyeth Corp | Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants) |
| CN1630631A (zh) * | 2001-12-05 | 2005-06-22 | 惠氏公司 | 新的文拉法星盐酸盐多晶型物及其制备方法 |
| US20040152710A1 (en) * | 2002-10-15 | 2004-08-05 | Deecher Darlene Coleman | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| FR2851163B1 (fr) * | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
| CA2574315A1 (en) * | 2004-07-22 | 2006-02-02 | Wyeth | Method for treating nervous system disorders and conditions |
-
2005
- 2005-07-21 US US11/186,279 patent/US20060020015A1/en not_active Abandoned
- 2005-07-21 JP JP2007522782A patent/JP2008507550A/ja active Pending
- 2005-07-21 AU AU2005266994A patent/AU2005266994A1/en not_active Abandoned
- 2005-07-21 WO PCT/US2005/025974 patent/WO2006012474A1/en not_active Ceased
- 2005-07-21 CN CNA2005800316183A patent/CN101410106A/zh active Pending
- 2005-07-21 CA CA002574310A patent/CA2574310A1/en not_active Abandoned
- 2005-07-21 EP EP05773617A patent/EP1773320A1/en not_active Withdrawn
- 2005-07-21 KR KR1020077004076A patent/KR20070034126A/ko not_active Abandoned
- 2005-07-21 RU RU2007102292/14A patent/RU2007102292A/ru not_active Application Discontinuation
- 2005-07-21 BR BRPI0512186-8A patent/BRPI0512186A/pt not_active IP Right Cessation
- 2005-07-21 MX MX2007000853A patent/MX2007000853A/es unknown
-
2007
- 2007-01-16 IL IL180731A patent/IL180731A0/en unknown
- 2007-01-19 ZA ZA200700578A patent/ZA200700578B/xx unknown
- 2007-02-16 NO NO20070912A patent/NO20070912L/no unknown
-
2011
- 2011-01-06 US US12/985,871 patent/US20120010260A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007000853A (es) | 2007-03-26 |
| IL180731A0 (en) | 2007-07-04 |
| NO20070912L (no) | 2007-04-20 |
| RU2007102292A (ru) | 2008-08-27 |
| AU2005266994A1 (en) | 2006-02-02 |
| CA2574310A1 (en) | 2006-02-02 |
| CN101410106A (zh) | 2009-04-15 |
| US20060020015A1 (en) | 2006-01-26 |
| EP1773320A1 (en) | 2007-04-18 |
| JP2008507550A (ja) | 2008-03-13 |
| KR20070034126A (ko) | 2007-03-27 |
| US20120010260A1 (en) | 2012-01-12 |
| BRPI0512186A (pt) | 2008-02-19 |
| WO2006012474A1 (en) | 2006-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1799119A4 (en) | DEVICE AND METHOD FOR TREATING WEIGHT DISTURBANCES | |
| EP1683067A4 (en) | METHOD FOR THE INVESTIGATION AND TREATMENT OF DISEASES | |
| IL184578A0 (en) | Method and composition for treating central nervous system disorders | |
| IL183985A0 (en) | Methods for treating autoimmune disorders | |
| EP1863562A4 (en) | METHOD FOR TREATING DEPRESSION, ATMOSPHERIC STATES AND FEASIBILITY WITH NEUROMODULATION | |
| IL180732A0 (en) | Method for treating nervous system disorders and conditions | |
| ZA200700918B (en) | Compositions and methods for treating eye disorders and conditions | |
| IL181922A0 (en) | Method for treating vasculitis | |
| IL179864A0 (en) | Compounds and methods for treating seizure and paroxysmal disorders | |
| ZA200610661B (en) | Compositions and methods for treating neurological disorders | |
| GB0409806D0 (en) | Nerve blocking method and system | |
| IL185861A0 (en) | Method and composition for treating mucosal disorders | |
| ZA200701560B (en) | System and method for treating wastewater | |
| EP1476147A4 (en) | METHODS OF TREATING VIEW DISORDERS | |
| GB0617734D0 (en) | Method of treating peripheral nerve disorders | |
| ZA200700580B (en) | Method for treating nervous system disorders and conditions | |
| ZA200700578B (en) | Method for treating nervous system disorders and conditions | |
| EP1834419A4 (en) | TARGETED DIFFUSION METHOD AND SYSTEM | |
| IL162288A0 (en) | Compositions and methods for treating neurodegenerative disorders | |
| IL193697A0 (en) | Methods for treating cognitive and other disorders | |
| IL163993A0 (en) | Method for treating cognitive disorders | |
| ZA200705502B (en) | System and method for diagnosis of brainstem disorders | |
| AU2003300042A1 (en) | Method and system for treating depressive and anxiety disorders | |
| EP1782821A4 (en) | MEDICAMENT AND METHOD FOR IMPROVING BRAIN FUNCTION | |
| EP1594473A4 (en) | COMPOSITION AND METHOD FOR THE TREATMENT OF AGE-RELATED DISEASES |